To appraise the clinical and cost-effectiveness of daratumumab in combination with Bortezomib, thalidomide and dexamethasone within its marketing authorisation for multiple myeloma
 
Status In progress
Process STA 2018
ID number 1510

Provisional Schedule

Committee meeting: 1 04 March 2021
Expected publication 19 April 2021

Project Team

Project lead Jo Ekeledo

Email enquiries

Evidence Review Group / Assessment Group Southampton Health Technology Assessment Centre (SHTAC), University of Southampton

Consultees

Companies sponsors Janssen-Cilag (daratumumab, bortezomib)
Others Department of Health and Social Care
  NHS City and Hackney CCG
  NHS England
  NHS Solihull CCG
  Welsh Government
Patient carer groups Anthony Nolan
  African Caribbean Leukaemia Trust
  Black Health Agency
  Blood Cancer UK
  Cancer Black Care
  Cancer Equality
  Cancer52
  DKMS
  Helen Rollason Cancer Charity
  Independent Cancer Patients Voice
  Leukaemia Cancer Society
  Leukaemia CARE
  Lymphoma Action
  Macmillan Cancer Support
  Maggie’s Centres
  Marie Curie
  Muslim Council of Britain
  Myeloma UK
  South Asian Health Foundation
  Specialised Healthcare Alliance
  Tenovus Cancer Care
Professional groups Association of Cancer Physicians
  British Blood Transfusion Society
  British Committee for Standards in Haematology
  British Geriatrics Society
  British Institute of Radiology
  British Psychosocial Oncology Society
  British Transplantation Society
  Cancer Research UK
  ESPRIT
  NHS Blood and Transplant
  Royal College of General Practitioners
  Royal College of Nursing
  Royal College of Pathologists
  Royal College of Physicians
  Royal College of Radiologists
  Royal Pharmaceutical Society
  Royal Society of Medicine
  Society and College of Radiographers
  UK Health Forum
  UK Myeloma Forum
  UK Clinical Pharmacy Association
  UK Oncology Nursing Society

Commentators

Associated public health groups Public Health England
  Public Health Wales
Comparator companies Advanz Pharma (dexamethasone)
  Alan Pharmaceuticals (thalidomide)
  Aspire Pharma (bortezomib, dexamethasone)
  Baxter Healthcare (cyclophosphamide)
  Celgene (thalidomide)
  Dr. Reddy's Laboratories (bortezomib)
  Rosemont Pharmaceuticals (dexamethasone)
  Sandoz (cyclophosphamide)
  Sigma Pharmaceuticals (dexamethasone)
  Thea Pharmaceuticals (dexamethasone)
  Thornton & Ross (bortezomib)
General commentators All Wales Therapeutics and Toxicology Centre
  Allied Health Professionals Federation
  Board of Community Health Councils in Wales
  British National Formulary
  Care Quality Commission
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare Products Regulatory Agency
  National Association of Primary Care
  National Pharmacy Association
  NHS Alliance
  NHS Confederation
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups Cochrane Haematological Malignancies Group
  Genomics England
  Institute of Cancer Research
  Leuka
  Leukaemia Busters
  MRC Clinical Trials Unit
  National Cancer Research Institute
  National Cancer Research Network
  National Institute for Health Research

Timeline

Key events during the development of the guidance:

Date Update
30 June 2020 Invitation to participate
11 May 2020 - 09 June 2020 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
08 May 2019 In progress. Referred 21 March 2017
09 January 2019 - 06 February 2019 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
27 April 0202 The Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of daratumumab in combination for untreated multiple myeloma when stem cell transplant is suitable. Following on from information received from the company this appraisal has now been scheduled into the work programme. The appraisal is anticipated to begin during late June 2020 when we will write to you about how you can get involved.

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance